Is hair loss a side effect of GLP‑1 (glucagon‑like peptide‑1) or GIP (glucose‑dependent insulinotropic polypeptide) receptor agonists such as semaglutide, liraglutide, dulaglutide, or tirzepatide, and how should it be evaluated and managed?

Hair Loss and GLP-1/GIP Receptor Agonists

Hair loss is an emerging adverse effect associated with GLP-1 and GIP receptor agonists, particularly semaglutide and tirzepatide, with the highest risk occurring in females using higher doses for weight loss. 1, 2, 3

Evidence from FDA Drug Labels

The FDA-approved prescribing information for dulaglutide (TRULICITY) and semaglutide (OZEMPIC) does not list hair loss or alopecia as a recognized adverse reaction in their official labeling 4, 5. This represents a gap between regulatory documentation and emerging real-world evidence.

Real-World Evidence and Risk Stratification

Agent-Specific Risk Profile

Semaglutide and tirzepatide demonstrate the highest incidence of hair loss among GLP-1/GIP agonists 1, 3. Pharmacovigilance data from the FDA Adverse Event Reporting System shows:

• Semaglutide: Significant positive association with alopecia (adjusted reporting odds ratio 1.23) and dose-dependent risk—doses <2mg weekly rarely implicated, while higher obesity-treatment doses show increased association 1, 3
• Tirzepatide: Most frequently linked to telogen effluvium, correlating with the greatest magnitude of weight loss 1
• Dulaglutide and liraglutide: Lower reported risk and negative associations in disproportionality analyses 1, 3

Patient-Specific Risk Factors

Multivariable regression analysis identifies three key predictors 2:

• Female sex: Disproportionately affected (adjusted OR for males = 0.36, meaning females have ~3x higher risk)
• Marital status: Married participants show highest odds (adjusted OR = 9.94)
• Specific agent: Tirzepatide (Mounjaro) users have 3-fold higher odds (adjusted OR = 3.02) compared to other agents

Clinical Characteristics

Alopecia Subtypes

When classified, two patterns predominate 1, 6:

1. Telogen effluvium: Most common, particularly with tirzepatide; associated with rapid weight loss
2. Androgenetic alopecia: Second most frequent pattern

Severity and Timing

• Severe hair loss occurs in 43.4% of tirzepatide users and 42.9% of liraglutide users when hair loss develops 2
• The hair loss is typically non-scarring and reversible 2
• Duration of medication use shows a trend toward higher risk at 6-12 months, though not statistically significant 2

Proposed Mechanism

Rapid weight loss emerges as the primary contributor, particularly for telogen effluvium 1. The magnitude of weight reduction correlates with hair loss risk, explaining why tirzepatide (producing the largest weight loss) shows the strongest association with telogen effluvium.

Clinical Management Algorithm

Pre-Treatment Counseling

1. Inform all patients starting semaglutide or tirzepatide about potential hair loss, especially:

   • Females
   • Those using doses >2mg weekly (semaglutide) or any dose of tirzepatide
   • Patients anticipating rapid weight loss

2. Set expectations: Hair loss is typically temporary and reversible upon discontinuation or dose reduction

Evaluation When Hair Loss Occurs

Do not perform routine thyroid ultrasound or extensive workup initially—this represents unnecessary testing given the temporal relationship with medication initiation.

Instead, assess:

• Timing: Onset relative to medication start (typically 3-6 months)
• Pattern: Diffuse thinning (telogen effluvium) vs. patterned loss (androgenetic)
• Rate of weight loss: >1-2 pounds per week increases risk
• Nutritional status: Protein intake, iron, zinc, vitamin D levels
• Psychological impact: Degree of distress affecting adherence

Management Strategy

For mild to moderate hair loss with acceptable psychological impact:

• Continue medication if metabolic benefits outweigh cosmetic concerns
• Optimize nutrition: protein ≥1g/kg/day, correct micronutrient deficiencies
• Slow weight loss rate if possible through dietary adjustment
• Reassure regarding reversibility

For severe hair loss or significant psychological distress:

• Switch from semaglutide/tirzepatide to dulaglutide or liraglutide, which show lower risk profiles 1, 3
• Consider dose reduction before complete discontinuation
• If switching agents, maintain SGLT-2 inhibitor for cardiovascular/renal protection per guidelines 7

Do not combine with other GLP-1 RAs or tirzepatide 7

Critical Caveats

• Over 1,000 spontaneous cases reported to FAERS, but causality remains unconfirmed through prospective randomized trials 6
• Most evidence lacks formal dermatological diagnostic confirmation 6
• The absence of hair loss in FDA labeling does not negate real-world signal detection 4, 5
• This side effect may reduce treatment adherence despite significant metabolic benefits 2

Practical Pitfall to Avoid

Do not dismiss patient concerns about hair loss as unrelated to medication simply because it is not in the FDA label. The pharmacovigilance signal is robust across multiple databases and warrants clinical acknowledgment and appropriate counseling.